Proapoptotic effect of endocannabinoids in prostate cancer cells

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1599-1608

  Orellana Serradell, O ^a   Poblete, C E ^a   Sanchez, C ^a   Castellon E A ^a   Gallegos, I ^b   Huidobro, C ^c   Llanos, M N ^a   Contreras, H R ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b Pathological Anatomy Service   (Chile)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Endocannabinoid receptors; Prostate cancer

Indexed keywords

2 ARACHIDONOYL GLYCEROL; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANANDAMIDE; ANTINEOPLASTIC AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CASPASE 3; METHANANDAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; RIMONABANT; UNCLASSIFIED DRUG; ACYLGLYCEROL; AKT1 PROTEIN, HUMAN; AMIDE; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID; GLYCERYL 2-ARACHIDONATE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TUMOR PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL COUNT; CELL CYCLE PROGRESSION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME REGULATION; FLOW CYTOMETRY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE HYPERTROPHY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; UPREGULATION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CELL CYCLE; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ADENOCARCINOMA; APOPTOSIS; ARACHIDONIC ACIDS; CELL CYCLE; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; NEOPLASM PROTEINS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84924917583     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3746     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Sark W: Epidemiology of prostate cancer and its precursors. Mod Pathol 10: 1038, 2004. (Epub ahead of print). doi: 10.1038/modpathol.3800074.
3. Tefekli A and Tunc M: Future prospects in the diagnosis and management of localized prostate cancer. Sci World J 2013: 347263, 2013.
4. Hsing A and Chokkalingam A: Prostate cancer epidemiology. Front Biosci 11: 1388-1413, 2006.
5. Porkka K and Visakorpi T: Molecular mechanisms of prostate cancer. Eur Urol 45: 683-691, 2004.
6. Lee C, Jia Z, Rahmatpanah F, Zhang Q, Zi X, McClelland M and Mercola D: Role of the adjacent stroma cells in prostate cancer development and progression: synergy between TGF-α and IGF signaling. Biomed Res Int 2014: 502093, 2014.
7. Bifulco M, Malfitano A, Pisanti S and Laezza C: Endocannabinoids in endocrine and related tumours. Endocr Relat Cancer 15: 391-408, 2008.
8. Hermanson DJ and Marnett LJ: Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev 30: 599-612, 2011.
9. Díaz-Laviada I: The endocannabinoid system in prostate cancer. Nat Rev Urol 8: 553-561, 2011.
10. Devane WA, Dysarz FA, Johnson MR, et al: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613, 1998.
11. Van Dross R, Soliman E, Jha S, et al: Receptor-dependent and receptor-independent endocannabinoid signaling: A therapeutic target for regulation of cancer growth. Life Sci 92: 463-466, 2013.
12. Guindon J and Hohmann AG: The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 16: 1447-1463, 2011.
13. Pisanti S and Bifulco M: Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res 60: 107-116, 2009.
14. Kirkham TC and Tucci SA: Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 5: 272-292, 2006.
15. Bovolin P, Cottone E, Pomatto V, et al: Endocannabinoids are involved in male vertebrate reproduction: regulatory mechanisms at central and gonadal level. Front Endocrinol (Lausanne) 5: 54, 2014.
16. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G and Zhang X: Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic-and antidepressant-like effects. J Clin Invest 115: 3104-3116, 2005.
17. Cridge BJ and Rosengren RJ: Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag Res 30: 301-313, 2013.
18. Batista LA, Gobira PH, Viana TG, et al: Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs. Behav Pharmacol 25: 425-433, 2014.
19. Bifulco M, Laezza C, Pisanti S and Gazzerro P: Cannabinoids and cancer: pros and cons of an antitumor strategy. Br J Pharmacol 148: 123-135, 2006.
20. Ramos JA and Bianco FJ: The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. Indian J Urol 28: 9-14, 2012
21. Melck D, Rueda D, Galve-Roperh I, et al: Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 463: 235-240, 1999.
22. Nithipatikom K, Endsley M, Isbell M, et al: 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 15: 8826-8830, 2004.
23. Portella G, Laezza C, Laccetti P, et al: Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17: 1771-1773, 2003
24. Melck D, De Petrocellis L, Orlando P, et al: Suppression of nerve growth factor Trk receptor and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141: 118-126, 2000.
25. Czifra G, Varga A, Nyeste K, et al: Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J. Cancer Res Clin Oncol 135: 507-514, 2009.
26. Mimeault M, Pommery N, Wattez N, et al: Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down?regulation and ceramide production. Postate 15: 1-12, 2003.
27. Ruiz L, Miguel A and Díaz-Laviada I: Delta9?tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor?independent mechanism. FEBS Lett 458: 400-404, 1999.
28. Sarfaraz S, Afaq F, Adhami VM and Mukhtar H: Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65: 1635-1641, 2005.
29. Gómez del Pulgar T, Velasco G and Guzmán M: The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347: 369-373, 2000.
30. Gómez del Pulgar T, Velasco G, Sánchez C, et al: De novo?synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 363: 183-188, 2002.
31. Rueda D, Galve-Roperh I, Haro A and Guzmán M: The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol 58: 814-820, 2000.
32. Mendoza P, Sánchez C, Contreras HR, et al: Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma. Int J Androl 32: 607-615, 2009.
33. Chunga S, Hammarstenb P, Josefssonb A, et al: A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 45: 174-182, 2009.
34. Brown L, Cascio M, Wahle K, et al: Cannabinoid receptordependent and-independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and?negative prostate cancer cell lines. Carcinogenesis 31: 1584-1591, 2010.
35. Nithipatikom K, Isbell M, Endsleya M, et al: Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat 94: 34-43, 2011.
36. Olea-Herrero N, Vara D, Malagarie-Cazenave S and Diaz?Laviada I: Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. Br J Cancer 101: 940-950, 2009.
37. Agudelo M, Newton C, Widen R, et al: Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes. J. Neuroimmune Pharmacol 3: 35-42, 2008.
38. Kelman Z: PCNA: structure, function and interactions. Oncogene 6: 629-640, 1997.
39. Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 1: 59-71, 2005.
40. Greenhough A, Patsos H, Ann C, et al: The cannabinoid D9-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer 121: 2172-2180, 2007.
41. De Petrocellis L, Ligresti A, Moriello A, et al: Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol 168: 79-102, 2013.
42. Hsu SS, Huang CJ, Cheng HH , et al: Anandamide-induced Ca2+ elevation leading to p38 MAPK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells. Toxicology 28: 21-29, 2007.